Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PDLIV - PDL Biopharma Inc TEMP


N/A
0   0%

Share volume: 0
Last Updated: Wed 01 Dec 2021 01:00:33 PM CET
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%

N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
59%
Profitability 75%
Dept financing 25%
Liquidity 0%
Performance 65%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
N/A
P/E Ratio 
N/A
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
113.982 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Dominique P. Monnet
Region: US
Website: http://www.pdl.com
Employees: 0
IPO year: -
Issue type:
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.

Recent news